A study to quantify misuse, abuse, dependence, and health resource use of extended-release morphine sulfate with sequestered naltrexone hydrochloride (ER-MSN; EMBEDA®), compared with non-abuse-deterrent extended-release morphine (ERM) products in Medicaid non-cancer patients
Latest Information Update: 09 May 2019
Price :
$35 *
At a glance
- Drugs Morphine/naltrexone (Primary) ; Morphine
- Indications Pain
- Focus Adverse reactions
- 09 May 2019 New trial record
- 01 Apr 2019 Results published in the Postgraduate Medicine